News archive
Showing 800 results
July 2023
-
Media Release
Novartis strengthens commitment to Beacon of Hope initiative, engages new collaborators to support clinical trial diversity, break down economic and education barriers
Advarra, Virb and BeeKeeperAI sign on to Beacon of Hope to provide suite of digital tools to facilitate clinical trials and research on healthcare inequities at Historically Black Medical School… -
Media Release
US FDA approves expanded indication for Novartis Leqvio® (inclisiran) to include treatment of adults with high LDL-C and who are at increased risk of heart disease
Expanded indication now enables broader use of Leqvio for LDL-C reduction in patients with primary hyperlipidemia (high LDL-C) 1 Leqvio can now be used earlier in LDL-C treatment as an adjunct to…
June 2023
-
Media Release
Novartis premieres powerful new docuseries at Tribeca Festival to shine a light on debilitating skin disease
Produced in partnership with advocate, journalist and filmmaker Jasmine IVANNA Espy, "The Beacons: Illuminating HS Stories" offers an intimate look into the journeys of six individuals living with… -
Media Release
Novartis Kisqali® significantly reduced the risk of recurrence by 25% across a broad population of patients with early breast cancer; clinically meaningful benefit was consistent across subgroups
Kisqali is the first and only CDK4/6 inhibitor to demonstrate a consistent, clinically meaningful benefit across a broad population of patients with HR+/HER2- early breast cancer, regardless of… -
Statement
Collaborating to address disparities in cancer screening
Novartis is supporting Black people to be the impact in their communities when it comes to education about early cancer detection
March 2023
-
Media Release
Novartis ribociclib (Kisqali®) only Category 1 preferred first-line treatment option for HR+/HER2- mBC in combination with an AI in updated NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
East Hanover, March 28, 2023 — Updates to the NCCN Guidelines® for breast cancer, released in January 2023, recommend ribociclib (Kisqali®) as the only Category 1 preferred CDK4/6 inhibitor (… -
Media Release
Novartis Kisqali® Phase III NATALEE trial meets primary endpoint at interim analysis demonstrating clinically meaningful benefit in broad population of patients with early breast cancer
Kisqali plus endocrine therapy (ET) significantly reduced the risk of disease recurrence compared to standard ET alone in the adjuvant setting1 NATALEE is the first and only positive… -
Media Release
Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer
New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months… -
Statement
Highlighting the Unmet Needs in Hidradenitis Suppurativa (HS)
Living with Hidradenitis Suppurativa (HS): Understanding the Patient Perspective